<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Frivold C</submitter><funding>U.S. Department of Health &amp; Human Services | Centers for Disease Control and Prevention (CDC)</funding><pagination>8490</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12475016</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>16(1)</volume><pubmed_abstract>Few population-based studies have evaluated the importance of pre-existing respiratory syncytial virus (RSV) antibody on RSV susceptibility among children and adults. We conducted a prospective, community-based cohort study among individuals aged 6 months-50 years in Oregon and Washington State, USA (June 2022-May 2023), with weekly symptom surveys and swab collection regardless of symptoms. Swabs were tested for RSV using RT-qPCR. Enrollment sera were tested for RSV prefusion F IgG binding (all participants) and neutralizing antibodies (pediatric participants). We detected 305 RSV illnesses among 3237 participants from 1188 households. Using proportional hazards regression, higher RSV binding antibody titers were associated with a lower estimated hazard of RSV among pediatric participants</pubmed_abstract><journal>Nature communications</journal><pubmed_title>Correlates of risk of respiratory syncytial virus disease: a prospective cohort study.</pubmed_title><pmcid>PMC12475016</pmcid><funding_grant_id>75D30121C12297</funding_grant_id><pubmed_authors>Piliper EA</pubmed_authors><pubmed_authors>Frivold C</pubmed_authors><pubmed_authors>Yetz N</pubmed_authors><pubmed_authors>Feldstein LR</pubmed_authors><pubmed_authors>Stone J</pubmed_authors><pubmed_authors>Hatchie TL</pubmed_authors><pubmed_authors>Naleway AL</pubmed_authors><pubmed_authors>Clark E</pubmed_authors><pubmed_authors>Mularski RA</pubmed_authors><pubmed_authors>Mohamed Bakhash SAK</pubmed_authors><pubmed_authors>Varga A</pubmed_authors><pubmed_authors>Wolock CJ</pubmed_authors><pubmed_authors>Lockwood CM</pubmed_authors><pubmed_authors>Han PD</pubmed_authors><pubmed_authors>Babu TM</pubmed_authors><pubmed_authors>Carone M</pubmed_authors><pubmed_authors>Greninger AL</pubmed_authors><pubmed_authors>Hoffman KL</pubmed_authors><pubmed_authors>Weil AA</pubmed_authors><pubmed_authors>Grindstaff S</pubmed_authors><pubmed_authors>Chu HY</pubmed_authors><pubmed_authors>Cox SN</pubmed_authors><pubmed_authors>Englund JA</pubmed_authors><pubmed_authors>Starita L</pubmed_authors><pubmed_authors>Marshall G</pubmed_authors><pubmed_authors>Reed J</pubmed_authors><pubmed_authors>Kuntz JL</pubmed_authors><pubmed_authors>Boisvert CL</pubmed_authors><pubmed_authors>Lo NK</pubmed_authors></additional><is_claimable>false</is_claimable><name>Correlates of risk of respiratory syncytial virus disease: a prospective cohort study.</name><description>Few population-based studies have evaluated the importance of pre-existing respiratory syncytial virus (RSV) antibody on RSV susceptibility among children and adults. We conducted a prospective, community-based cohort study among individuals aged 6 months-50 years in Oregon and Washington State, USA (June 2022-May 2023), with weekly symptom surveys and swab collection regardless of symptoms. Swabs were tested for RSV using RT-qPCR. Enrollment sera were tested for RSV prefusion F IgG binding (all participants) and neutralizing antibodies (pediatric participants). We detected 305 RSV illnesses among 3237 participants from 1188 households. Using proportional hazards regression, higher RSV binding antibody titers were associated with a lower estimated hazard of RSV among pediatric participants</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Sep</publication><modification>2026-06-03T21:35:49.366Z</modification><creation>2026-05-02T03:07:34.391Z</creation></dates><accession>S-EPMC12475016</accession><cross_references><pubmed>41006233</pubmed><doi>10.1038/s41467-025-63434-x</doi></cross_references></HashMap>